Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: A randomized controlled trial

American Journal of Gastroenterology

Volumn 104, Issue 11, 2009, Pages 2779-2787

  Miwa, Hiroto ^a   Nagahara, A ^b   Tominaga, K ^c   Yokoyama, T ^d   Sawada, Y ^e   Inoue, K ^f   Ashida, Kiyoshi ^g   Fukuchi, T ^g   Hojo, M ^b   Yamashita, H ^g   Tomita, T ^a   Hori, K ^a   Oshima, T ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^e Takarazuka Municipal Hospital   (Japan)

^f MATSUE RED CROSS HOSPITAL   (Japan)

^g SAISEIKAI NAKATSU HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TANDOSPIRONE;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOLOGIC TEST; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 8; STATE TRAIT ANXIETY INVENTORY; TREATMENT DURATION; UPPER ABDOMINAL PAIN;

ADULT; ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSPEPSIA; FEMALE; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; PATIENT SATISFACTION; PIPERAZINES; PROBABILITY; PYRIMIDINES; QUALITY OF LIFE; REFERENCE VALUES; RISK ASSESSMENT; SEROTONIN RECEPTOR AGONISTS; SEVERITY OF ILLNESS INDEX; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 72049132921     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.427     Document Type: Article

References (33)

1. Talley NJ, Stanghellini V, Heading RC et al. Functional gastroduodenal disorders. Gut 1999;45:S1137-42.
2. Kawamura A, Adachi K, Takashima T et al. Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population. J Gastroenterol Hepatol 2001;16:384-388
3. Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/ International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol 1999;231:S20-8. (Pubitemid 29510674)
4. Sung JJ, Chung SC, Ling TK et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995;332:139-142
5. Hentschel E, Brandstätter G, Dragosics B e t al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993;328:308-312
6. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994;272:65-69
7. European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997;41:8-13.
8. Fisher RS, Parkman HP. Management of nonulcer dyspepsia. N Engl J Med 1998;339:1376-1381
9. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132:397-414. (Pubitemid 46127672)
10. Coulie B, Tack J, Janssens J. Influence of buspirone-induced fundus relaxation on the perception of gastric distension in man . Gastroenterology 1997;110: A767 abstract. (Pubitemid 30305809)
11. Talley NJ, Vakil N. Practice parameters committee of the American college of gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005;100:2324-2337
12. Tack J, Van Elzen B, Tytgat G et al. A placebo controlled trial of the 5-HT1A aginist R137696 on symptoms, visceral hypersensitivity and impaired fundic accommodation in functional dyspepsia. Gastroenterology 2004;126:A70 abstract.
13. Miwa H, Hirai S, Nagahara A et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients - a double-blind placebo-controlled study. Aliment Pharmacol Ther 2000;14:317-324
14. Miwa H, Osada T, Nagahara A et al. Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia - A double blind placebo controlled study in Japan . J Gastroenterol Hepatol 2006;21:1826-1831 (Pubitemid 44657004)
15. Fukuhara S, Suzukamo Y. Instruments for measuring Health-related Quality of Life-SF8 and SF36. J Clin Exp Med [Igaku no Ayumi] 2005;213: 133-136 (in Japanese).
16. Nakazato K, Mizuguchi T. Development and validation of Japanese version of State-Trait anxiety inventory - a study with female subjects . Jpn J Psychosom Med [AShinshin-Igaku] 1982;22:107-112 (in Japanese).
17. Erckenbrecht JF, Schafer R, Kohler G et al. Dyspeptic symptoms in healthy volunteers with stress are related to stress-induced increase of anxiety - results of prospective study with a longterm " physiological " stress model. J Gastrointest Motil 1993;5:189-194
18. Barry S , Dinan TG . Functional dyspepsia: are psychosocial factors of relevance? World J Gastroenterol 2006;12:2701-2707
19. Talley NJ, Zinsmeister AR , Schleck CD et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259-1268
20. Kroenke K, Jackson JL, Chamberlin J. Depressive and anxiety disorders in patients presenting with physical complaints: clinical predictors and outcome. Am J Med 1997;103:339-347 (Pubitemid 27506238)
21. Jackson JL, O ' Malley PG, Tomkins G et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72. (Pubitemid 30058279)
22. Hojo M, Miwa H, Yokoyama T et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005;40:1036-1042 (Pubitemid 43055287)
23. Hamik A, Oksenberg D, Fischette C et al. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 1990;28:99-109. (Pubitemid 20226391)
24. Murasaki M, Mori A, Endo S et al. Late phase II study of a new anxiolytic, SM 3997 (tandospirone) on neurosis. Rinsho Hyoka 1992;20:259-293 .
25. Tamai H, Komaki G, Kubota S et al. Th e clinical effi cacy of a 5-HT1A agonist, SM-3997, in the treatment of bulimia. Int J Obes 1990;14: 289-292 (Pubitemid 20150413)
26. Kinoshita Y, Hashimoto T, Kawamura ura A e t al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 2005;21:S37-41.
27. Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther 2005;21:S32-6. (Pubitemid 40806578)
28. Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006;55:1685-1691 (Pubitemid 44893562)
29. Boeckxstaens G, Tytgut G, Wajs E et al. The influence of the novel 5-HT1A agonist R137696 on the proximal stomach function in healthy volunteers. Neurogastroenterol Motil 2006;18:919-926 (Pubitemid 44358862)
30. Barradell LB, Fitton A. Tandospirone. CNS Drugs 1996;5:147-153 .
31. Murasaki M, Mori A, Endo S et al. Late Phase II study of a new anxiolytic, SM-3997 (tandospirone), on various neurosis. Rinsho Hyoka 1992; 20: 259-293 (in Japanese).
32. Musial F, Klosterhalfen S, Enck P. Placebo responses in patients with gastrointestinal disorders. World J Gastroenterol 2007;13:3425-3429 (Pubitemid 47162015)
33. Kindt S, Tack J. Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders. Neurogastroenterol Motil 2007;19:S32-9. (Pubitemid 47037964)